~~<i id='CDE685650D'><strike id='CDE685650D'><tt id='CDE685650D'><pre id='CDE685650D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：leisure time 2025-09-06 04:35:42 - browse：59368

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

focus

hotspot

focus

hotspot

leisure time

Inthis1895photo,nursesanddoctorsinoculateachildwithdiphtheriaantitoxinatthePasteurInstituteinNewYork

WSS

United colonoscopy coverage change 'may cost lives,' doctors say

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cholera vaccine supplies dangerously low, outbreaks surging

Color Health wants to make cancer screenings convenient

Readout Newsletter: Beam, Prozac, "TechBio" and more

Childhood vaccination ad campaign launches in the U.K.

knowledge

entertainment

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Bright Health sells Medicare Advantage business to Molina

Duchenne breakthrough therapy leaves behind pioneering families

Jerome Adams on the need for new antivirals for Covid

Sports medicine is finally prioritizing gender equality

CDC advisory group OKs chikungunya vaccine

The high cost of giving birth even with insurance

Change Healthcare cyberattack shows risk of industry consolidation

State Dept. review finds Biden bears some blame for Afghanistan failures

Elisabeth Bik tackles the widespread issue of research misconduct

focus

Alkermes shareholders re

Laying a path for careers in science

Continuity nursing helped my family in our darkest PICU moments

How one medical school became remarkably diverse

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Psychedelics group wrestles with new pharma identity

hotspot

focus

hotspot

leisure time